The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Metformin revisited: re‐evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents
Abstract
Background: The usefulness of metformin as an oral antidiabetic agent is widely accepted. However, several other classes of oral antidiabetic agents have been recently introduced, raising the need to evaluate the role of metformin as initial therapy and in combination with these newer drugs for treatment of type 2 diabetes mellitus (DM). Methods: Synthesis of information was preceded by a comprehensive review of the English language literature using Medline. We also reviewed bibliographies of relevant articles. The studies most pertinent to the mechanism of action, efficacy, toxicity and administration of metformin were selected for citation in this review. Results: Metformin acts by increasing tissue sensitivity to insulin, principally in the liver. Beneficial properties of metformin include weight reduction, favourable effects on the lipid profile and the fibrinolytic pathway, and improvement of ovarian function in some insulin‐resistant women. It does not cause hyperinsulinaemia or hypoglycaemia. Metformin is effective as monotherapy and, in combination with both insulin secretagogues and thiazolidinediones (TZDs), may obviate the need for insulin treatment. Several fixed‐dose combination pills containing metformin and other agents are available. A protocol for the initiation of therapy with contemporary oral agents for type 2 DM is presented, with emphasis on the continuing central role of metformin. Conclusions: Metformin remains a safe and effective agent for the therapy of patients with type 2 DM. It is useful as monotherapy or in combination regimens with the newer insulin secretagogues, TZDs or insulin. It is still in most circumstances the agent of choice for initial therapy of the typical obese patient with type 2 DM and mild to moderate hyperglycaemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652
U.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
Bailey, C. J., & Turner, R. C. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602293340906 · Cited by 1,726
El-Mir, M.-Y., Nogueira, V., Fontaine, E., Avéret, N., Rigoulet, M., & Leverve, X. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.1.223 · Cited by 1,399
Efficacy of Metformin in Patients with Non-Insulin-Dependent Diabetes Mellitus
DeFronzo, R. A., & Goodman, A. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330902 · Cited by 1,368
Metabolic effects of metformin in non-insulin-dependent diabetes mellitus
Stumvoll, M., Nurjhan, N., Perriello, G., Dailey, G., & Gerich, J. E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330903 · Cited by 1,148
Velazquez, E. M., Mendoza, S., Hamer, T., Sosa, F., & Glueck, C. J. (1994) · Metabolism · doi:10.1016/0026-0495(94)90209-7 · Cited by 865
Efficacy and Metabolic Effects of Metformin and Troglitazone in Type II Diabetes Mellitus
Inzucchi, S. E., Maggs, D. G., Spollett, G. R., Page, S. L., Rife, F. S., Walton, V., & Shulman, G. I. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381303 · Cited by 794
Improved Endothelial Function With Metformin in Type 2 Diabetes Mellitus
Mather, K. J., Verma, S., & Anderson, T. J. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01129-9 · Cited by 513
Research works printed but not linked: 106
- Medvei VC, 1993, The History of Clinical Endocrinology, 365
- 10.1016/S0021-9258(18)86579-6 · DOI · Paper page
- 10.2337/diacare.12.8.553 · DOI · Paper page
- 10.1007/BF01263444 · DOI · Paper page
- 10.7326/0003-4819-87-5-591 · DOI
- 10.7326/0003-4819-83-4-567 · DOI
- Lucis OJ, 1983, The status of metformin in Canada, Can Med Assoc J, 128, 24
- Clarke BF, 1979, Biguanide treatment in the management of non‐insulin‐independent (maturity‐onset) diabetes: clinical experience with metformin, Res Clin Forums, 1, 53
- 10.1111/j.1464-5491.1987.tb00895.x · DOI
- 10.1007/BF00285334 · DOI
- 10.1136/bmj.4.5622.25 · DOI
- 10.2337/diabetes.32.12.1083 · doi:10.2337/diabetes.32.12.1083
- 10.2337/diab.36.5.632 · DOI · Paper page
- Ferner RE, 1988, Impaired beta‐cell responses improve when fasting blood glucose concentration is reduced in non‐insulin‐dependent diabetes, Q J Med, 66, 137
- 10.1146/annurev.pa.15.040175.002031 · DOI
- Hermann LS, 1979, Metformin: a review of its pharmacological properties and therapeutic use, Diabetes Metab, 5, 233
- Sterne J, 1984, Metformin: pharmacological mechanisms of the antidiabetic and antilipidic effects and clinical consequences, R Soc Med (Int Congr Symp Ser), 48, 3
- 10.2337/diab.17.8.492 · DOI
- 10.1056/NEJM197703032960906 · DOI
- 10.1210/jc.74.5.1020 · doi:10.1210/jc.74.5.1020
- 10.1530/acta.0.1200257 · DOI
- 10.2337/diacare.13.6.696 · DOI · Paper page
- 10.1111/j.1445-5994.1991.tb01375.x · DOI
- Fendri S, 1993, Metformin effects on peripheral sensitivity to insulin in non diabetic obese subjects, Diabetes Metab, 19, 245
- 10.2337/diab.43.7.920 · DOI · Paper page
- Galuska D, 1991, Metformin increases insulin‐stimulated glucose transport in insulin‐resistant human skeletal muscle, Diabetes Metab, 17, 159
- 10.1210/en.130.5.2535 · doi:10.1210/en.130.5.2535
- 10.1016/S0889-8529(18)30221-4 · DOI
- 10.2337/diacare.17.10.1100 · DOI · Paper page
- 10.1007/BF00403956 · DOI
- 10.1210/en.137.7.2990 · doi:10.1210/en.137.7.2990
- Valensi P, 2002, In vivo kinetics of 123 iodine‐labelled insulin in skeletal muscle of patients with type 2 diabetes. Effect of metformin, Diabetes Metab, 28, 95
- 10.1016/0026-0495(90)90259-F · DOI
- 10.2337/diabetes.42.8.1159 · DOI
- 10.2165/00003495-199958001-00009 · DOI · Paper page
- 10.1210/jc.2002-021394 · DOI · Paper page
- 10.2337/diabetes.48.6.1251 · DOI
- 10.1111/j.1432-1033.1993.tb17886.x · DOI
- 10.2337/diab.46.9.1406 · DOI
- 10.1016/S0005-2736(01)00352-2 · DOI
- 10.1016/S0006-2952(02)00858-4 · DOI
- 10.1074/jbc.M202489200 · DOI · Paper page
- 10.2337/diabetes.51.7.2074 · DOI · Paper page
- 10.2337/diabetes.49.6.896 · DOI · Paper page
- 10.2337/diab.37.12.1595 · DOI · Paper page
- 10.2337/diacare.16.7.1035 · DOI
- 10.1136/bmj.2.6102.1576 · DOI
- 10.2337/diabetes.51.12.3479 · DOI · Paper page
- 10.1210/jc.2002-021786 · DOI · Paper page
- Vigneri R, 1991, Treatment of NIDDM patients with secondary failure to glyburide: comparison of the addition of either metformin or bed‐time NPH insulin to glyburide, Diabetes Metab, 17, 232
- 10.1185/03007998209110114 · doi:10.1185/03007998209110114
- 10.1177/014107688908200213 · DOI
- Haupt E, 1991, Oral antidiabetic combination therapy with sulphonylureas and metformin, Diabetes Metab, 17, 224
- 10.1001/jama.283.13.1695 · DOI · Paper page
- 10.1111/j.1464-5491.1988.tb01074.x · DOI
- 10.1007/BF02581246 · DOI
- Klein W, 1991, Sulfonylurea‐metformin combination versus sulfonylurea‐insulin combination in secondary failures to sulfonylurea monotherapy, Diabetes Metab, 17, 235
- 10.2337/diacare.25.3.542 · DOI · Paper page
- 10.1007/BF00315466 · DOI · Paper page
- 10.2337/diacare.16.4.621 · DOI · Paper page
- 10.1016/S0140-6736(65)92383-4 · DOI
- Gin H, 1988, Effect of metformin on platelet hyperaggregation in the insulin‐dependent diabetic, Diabetes Metab, 14, 596
- 10.1136/bmj.310.6972.83 · DOI · Paper page
- 10.1385/ENDO:20:3:215 · DOI
- 10.1016/S0140-6736(98)07037-8 · DOI · Paper page
- 10.2337/diacare.25.12.2244 · DOI · Paper page
- 10.1007/BF01221950 · DOI · Paper page
- Coetzee EJ, 1980, Pregnancy in established non‐insulin‐dependent diabetics. A five‐and‐a‐half year study at Groote Schuur Hospital, S Afr Med J, 58, 795
- Coetzee EJ, 1984, Oral hypoglycaemics in the first trimester and fetal outcome, S Afr Med J, 65, 635
- 10.1002/tera.1420490405 · DOI
- 10.1046/j.1464-5491.2000.00314.x · DOI · Paper page
- 10.1093/ajcn/71.5.1242s · DOI · Paper page
- 10.1056/NEJM199806253382603 · DOI · Paper page
- 10.1007/s004040100176 · DOI
- 10.1016/S0015-0282(01)03202-2 · DOI · Paper page
- 10.1016/S0015-0282(00)01666-6 · DOI · Paper page
- 10.1210/jcem.87.2.8207 · DOI · Paper page
- 10.1016/S0015-0282(03)00734-9 · DOI
- 10.2165/00003495-199549050-00007 · DOI · Paper page
- 10.2165/00002018-199411040-00002 · DOI · Paper page
- Campbell I, 1985, Metformin and the sulfonylureas: the comparative risk, Horm Metab Res Suppl, 15, 105
- 10.2337/diacare.15.6.755 · DOI · Paper page
- 10.1016/S0140-6736(65)91893-3 · DOI
- 10.1136/bmj.2.6135.464 · DOI
- Hermann L, 1984, Metabolic effects of metformin in relation to clinical effects and side‐effects, R Soc Med (Int Congr Symp Ser), 48, 3
- 10.1136/bmj.280.6225.1214 · DOI · Paper page
- Scheen AJ, 1994, Reduction of the acute bioavailability of metformin by the alpha‐glucosidase inhibitor acarbose in normal man, Eur J Clin Invest, 24, 50, 10.1111/j.1365-2362.1994.tb02257.x · DOI · Paper page
- 10.1111/j.1365-2125.1987.tb03090.x · DOI · Paper page
- 10.2337/diacare.26.7.2069 · DOI
- 10.1002/cpt1978246683 · DOI · Paper page
- Lalau JD, 1990, Type 2 diabetes in the elderly: an assessment of metformin (metformin in the elderly), Int J Clin Pharmacol Ther Toxicol, 28, 329
- 10.1016/S0002-9343(97)00254-4 · DOI · Paper page
- 10.2337/diacare.15.4.539 · DOI
- Groop L, 1991, Treatment strategies for secondary sulfonylurea failure. Should we start insulin or add metformin? Is there a place for intermittent insulin therapy?, Diabetes Metab, 17, 218
- 10.1007/BF02581286 · DOI
- 10.2337/diacare.22.1.119 · DOI · Paper page
- 10.2337/diacare.26.7.2063 · DOI
- 10.1016/S0149-2918(00)83039-8 · DOI · Paper page
- 10.1046/j.1463-1326.2003.00258.x · DOI
- 10.1002/dmrr.264 · DOI
- 10.1016/S0002-9343(00)00338-7 · DOI
- Leblanc H, 1987, Value of combined subcutaneous infusion of insulin and metformin in 10 insulin‐dependent obese diabetics, Diabetes Metab, 13, 613
- 10.1016/0002-9343(91)90041-U · DOI
- Yang J, 2003, Efffect of addition of low‐dose rosiglitazone to sulphonylurea therapy on glycemic control in type 2 diabetic patients, Chin Med J (Engl), 116, 785
- 10.1111/j.1464-5491.2004.01083.x · DOI
- 10.2337/diacare.25.10.1691 · DOI
Cited by
Metformin—mode of action and clinical implications for diabetes and cancer
Pernicova, I., & Korbonits, M. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.256 · Cited by 1,349
Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP
Miller, R. A., Chu, Q., Xie, J., Foretz, M., Viollet, B., & Birnbaum, M. J. (2013) · Nature · doi:10.1038/nature11808 · Cited by 833
Metformin: An Old But Still the Best Treatment for Type 2 Diabetes
Rojas, L. B. A., & Gomes, M. B. (2013) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-5-6 · Cited by 567
Nyenwe, E. A., Jerkins, T. W., Umpierrez, G. E., & Kitabchi, A. E. (2011) · Metabolism · doi:10.1016/j.metabol.2010.09.010 · Cited by 343
The Therapeutic Potential of Metformin in Neurodegenerative Diseases
Rotermund, C., Machetanz, G., & Fitzgerald, J. C. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00400 · Cited by 304
Metadata
- Authors
- Goodarzi, M. O., & Bryer‐Ash, M.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2004-12-13
- Volume
- 7
- Issue
- 6
- Pages
- 654-665
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2039006908
- Cited by
- 162
- References
- 17
- FWCI
- 1.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Metformin revisited: re‐evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents. https://app.cochat.ai/papers/10.1111/j.1463-1326.2004.00448.x
- The paper
- Goodarzi, M. O., & Bryer‐Ash, M. (2005). Metformin revisited: re‐evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2004.00448.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.